Table 5.
Main characteristics of recent eligible studies (operable-stage NSCLC).
| Author Year | Country | Study | Time frame | Sample size | Age | TNM stage | Follow-up | Biomarkers | Cutoff value | Outcome | Validation |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Yusuke (52) 2015 | Japan | Retro | 2000-2008 | 343 | 68 (25-87) | I | 73.5 (15-159) | NLR | 2.5 | OS RFS | No |
| Yuan (53) 2017 | China | Retro | 2005-2009 | 1466 | I-IIIA | 69.9 (64-75) | NLR | 2.06 | OS | No | |
| PLR | 204 | ||||||||||
| MLR | 0.35 | ||||||||||
| Gao (49) 2018 | China | Retro | 2009-2011 | 410 | 60 (35-82) | I-IIIA | 54 (3-96) | SII | 395.4 | OS | No |
| NLR | 1.9 | ||||||||||
| PLR | 108.8 | ||||||||||
| LMR | 3.6 | ||||||||||
| Huang (18) 2018 | China | Retro | 2006-2009 | 589 | 60 (24-82) | I-IIIA | 44 | NLR | 2.3 | OS | No |
| Fibrinogen | 3.48 | DFS | |||||||||
| Guo (48) 2019 | China | Retro | 2006-2012 | 569 | 60 (27-80) | I-III | 60.3(0.9-146.7) | SII | 419.6 | OS | No |
| NLR | 1.74 | ||||||||||
| PLR | 88.7 | ||||||||||
| Li (54) 2019 | China | Retro | 2013-2015 | 390 | I-IIIA | 50 (12-66) | SIRI | 0.99 | OS | No | |
| NLR | 3.60 | DFS | |||||||||
| PLR | 106.13 | ||||||||||
| LMR | 2.40 | ||||||||||
| Shoji (55) 2020 | Japan | Retro | 2006-2012 | 529 | 68 (30–91) | IA | 63 (0-144) | SII | 358 | RFS | No |
| NLR | 1.5 | ||||||||||
| PLR | 184 | ||||||||||
| MLR | 0.19 |
NLR, neutrophil-to-lymphocyte ratio; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; MLR, monocyte/lymphocyte ratio; PLR, platelet/lymphocyte ratio; LMR, lymphocyte/monocyte ratio; RFS, recurrence-free survival; OS, overall survival; DFS, disease-free survival.